|
Management
Goal and Strategies
The
Company’s goal is to have the Company become an industry-leading biotechnology company using
the Cell-in-a-Box® technology as a platform upon which treatments for cancer and diabetes are developed
and obtain marketing approval for these treatments by regulatory agencies in the United States, the European Union, Australia
and Canada.
The Company’s
strategies to achieve this goal consist of the following:
| |
· |
The completion of the preparations for a Phase 2b clinical
trial in advanced, inoperable non-metastatic pancreatic cancer and its associated pain to be conducted by Translational Drug
Development, LLC (“TD2”) in the United States with study sites in Europe and Australia; |
| |
· |
The completion of the preparations for a clinical trial that
will examine the effectiveness of the Company’s pancreatic cancer treatment in reducing the accumulation of malignant
ascites fluid in the abdomen that is characteristic of pancreatic and other abdominal cancers. This clinical trial will be
conducted by TD2 in the United States; |
| |
· |
The completion of preclinical studies that involve the encapsulation
of the Melligen cells using the Cell-in-a-Box® technology to develop a treatment for Type 1 diabetes and Type
2 insulin-dependent diabetes; |
| |
· |
The enhancement of the Company’s ability to expand into
the biotechnology arena through further research and partnering agreements in cancer and diabetes; |
| |
· |
The acquisition of contracts that generate revenue or provide
research and development capital utilizing the Company’s sublicensing rights; |
| |
· |
The further development of uses of the Cell-in-a-Box®
technology platform through contracts, licensing agreements and joint ventures with other companies; and |
| |
· |
The completion of testing, expansion and marketing of existing
and newly derived product candidates. |
|